As of July 10, 2026, a research trial that could reshape how advanced prostate cancer is treated — and how oncology imaging companies compete — quietly launched with remarkably little fanfare outside specialist circles.
What Happened: The Trial Behind the Headline
79 out of 100. That is roughly the share of advanced prostate cancer patients who show measurable tumor marker decline after a single cycle of radioligand therapy — a targeted treatment that uses a radioactive molecule engineered to seek out and destroy cancer cells. Despite those numbers, the therapy still faces a stubborn clinical problem: doctors cannot reliably predict before treatment which patients will respond. A new research collaboration announced July 8, 2026 is designed to change that.
According to Google News, citing Imaging Technology News and an official statement from the Mayo Clinic News Network, GE HealthCare and Mayo Clinic formally launched the MI-BET trial — short for Molecular Imaging Biomarker-Based End of Therapy Trial — to monitor tumor response in real time throughout radioligand therapy for advanced prostate cancer. The study pairs GE HealthCare's StarGuide SPECT/CT imaging system with MIM Software's MIM LesionID Pro, creating a detailed map of tumor activity while simultaneously tracking blood-based biomarkers and clinical outcomes. The explicit goal, as described by the Mayo Clinic research team, is to integrate imaging data with clinical outcomes and blood-based biomarkers to explore combined insights that may help inform treatment decisions and potentially support predictive markers for patient response — in plain English, a way to tell a clinician ahead of time whether a specific patient is likely to respond before committing to a $40,000-per-cycle treatment course.
The MI-BET trial sits inside a broader joint initiative called GEMINI-RT, which targets four pillars of oncology care: automation, predictive oncology, multi-modal therapies, and outpatient monitoring. A joint statement from the organizations describes GEMINI-RT as combining "Mayo Clinic's world-class clinical and research expertise with GE HealthCare's leading technical and engineering innovation in oncology care and radiation therapy." Research activities are based at Mayo Clinic's Rochester, Minnesota campus, under the Strategic Radiology Research Alliance the two organizations signed in 2023.
What the Evidence Actually Shows
The evidence base for radioligand therapy itself is already solid by clinical standards — and it is worth separating what is known from what remains experimental, because conflating the two is where single-study headlines mislead people.
As of July 10, 2026, clinical data confirms 79% of patients experience a PSA (prostate-specific antigen — a protein produced by prostate cells that doctors use to track cancer activity) decline after the first treatment cycle, and 70.6% achieve a drop of 50% or greater. In oncology, a 50%-plus decline is treated as a meaningful response signal — the rough equivalent of a material improvement in a patient's disease trajectory. The FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan to patients with pre-taxane (before standard chemotherapy) metastatic castration-resistant prostate cancer in March 2025, which substantially widened the eligible population. Coverage has followed: as of July 10, 2026, the therapy is covered by Medicare and most private insurers.
The honest gap — and what MI-BET is directly targeting — is heterogeneity. Those aggregate response rates mask real patient-to-patient variation. The systematic review evidence confirms the therapy works at the population level; the personalization layer, the ability to predict individual response before treatment begins, is still being built. That is the hypothesis the new trial is testing, and the distinction matters both clinically and for any investment thesis built around this technology sector.
Why Healthcare Investors Are Paying Attention
The financial backdrop makes the clinical story far more consequential for investors. As of July 10, 2026, the global theranostics market (the combined diagnostics-plus-therapy field that radioligand treatment anchors) is estimated at between $2.69 billion and $9.2 billion — a wide range reflecting genuine market uncertainty about adoption pace. Projections for 2033 to 2035 point to $7.56 billion to $31.5 billion, implying compound annual growth rates of 13.1% to 15.7%.
Chart: Global theranostics market size — 2025 high-end estimate vs. 2033 high-end projection. Source: industry market research as of July 10, 2026.
North America holds 39.8% of that market today, with Asia-Pacific identified as the fastest-growing region. For GE HealthCare specifically, the company reported Q1 2026 revenues of $5.1 billion, up 7.4% year-over-year, with organic revenue growth of 2.9% driven by its Pharmaceutical Diagnostics and Imaging divisions — the exact segments positioned to benefit from theranostics expansion. The company carries a $21.8 billion backlog, supporting analyst estimates of 3-4% organic revenue growth for the full year.
GE HealthCare also closed its $2.3 billion acquisition of Intelerad in Q1 2026, adding cloud-enabled enterprise imaging to a hardware and software portfolio that now spans the StarGuide SPECT/CT used in MI-BET, MIM LesionID Pro software, and FDA clearances in 2026 for both the Photonova Spectra photon-counting CT and a next-generation SIGNA MRI system. Anyone building a healthcare allocation in their investment portfolio should note that GE HealthCare's exposure to theranostics is not a single product bet — it is a stack. As the Investor NewLens analysis of defensive sector performance notes, medical technology companies with recurring imaging and diagnostics revenue tend to behave differently from the broader market during economic stress — a relevant frame given current macro uncertainty.
AI Is the Real Connective Tissue
The GEMINI-RT initiative's four pillars — automation, predictive oncology, multi-modal therapies, and outpatient monitoring — map almost exactly onto where AI is making documented clinical progress in 2026. Broader medical imaging research from 2026 shows AI-assisted cancer detection now accounts for 80% of oncology diagnostic applications, with 70-90% of U.S. hospitals using some form of AI in radiology. AI-assisted mammography has demonstrated cancer detection rate improvements of 5-9% alongside sensitivity gains up to 9.4% specifically in patients with dense breast tissue, according to 2026 medical imaging research — an effect size modest enough to be credible and consistent enough to be clinically meaningful.
The MI-BET trial's architecture — imaging data, blood biomarkers, and clinical outcomes feeding a unified analytical model — is essentially constructing a training dataset for predictive AI tools. If the study identifies reliable biomarker signals that precede or predict treatment response, those signals become the input features for machine learning models that could eventually automate patient stratification before any radioactive molecule is administered. Mayo Clinic's existing AI infrastructure supports this ambition: the institution entered a 10-year collaboration with Google in 2019 on AI-enabled drug discovery, and partnered with Merck in 2025 to apply AI and multimodal clinical data to drug development. GE HealthCare brings the imaging hardware and cleared software stack to operationalize whatever the trials find.
Three Things Worth Tracking
GE HealthCare (ticker: GEHC) breaks out revenue by division. The Pharmaceutical Diagnostics and Imaging divisions are the direct financial beneficiaries of theranostics growth — they drove the Q1 2026 organic revenue increase. Anyone doing financial planning with healthcare equity exposure should monitor these segment numbers quarterly, not just the headline revenue figure, to assess whether theranostics adoption is translating into actual volume.
As of July 10, 2026, radioligand therapy at approximately $40,000 per cycle is covered by Medicare and most private insurers for existing approved indications. The speed at which new patient profiles and cancer types gain insurance coverage — often following FDA expansion approvals — is the single variable most likely to determine whether North America's 39.8% market share translates into accelerating revenue for imaging and therapy companies.
The March 2025 lutetium Lu 177 expansion to pre-taxane patients already widened the eligible population meaningfully. MI-BET is designed partly to generate clinical evidence that could support future approval expansions. FDA clearance timelines are a practical leading indicator for investors in this space — each new indication directly expands the addressable market for the imaging infrastructure GE HealthCare is building.
Frequently Asked Questions
What is theranostics cancer treatment and how does it work?
Theranostics combines the words therapy and diagnostics. The approach uses a single engineered molecule — often radioactive — that both identifies and attacks cancer cells in the same treatment. In prostate cancer radioligand therapy, the molecule targets PSMA (prostate-specific membrane antigen), a protein overexpressed on prostate cancer cells, delivering targeted radiation directly to tumors while limiting exposure to surrounding healthy tissue. As of July 10, 2026, it is an FDA-approved treatment category with documented clinical response rates in advanced prostate cancer.
How much does radioligand therapy cost for prostate cancer, and is it covered by insurance?
As of July 10, 2026, radioligand therapy for prostate cancer costs approximately $40,000 per treatment cycle. Most patients receive multiple cycles. Medicare and most private insurers cover the therapy for eligible patients following FDA approval, though prior authorization requirements and out-of-pocket cost-sharing vary by plan. Patients should confirm specific coverage terms with their insurer and treating oncologist before starting treatment.
What is the success rate of radioligand therapy for prostate cancer?
Clinical data as of July 10, 2026 shows 79% of patients experience a PSA (prostate-specific antigen) decline after the first cycle, with 70.6% achieving a decline of 50% or greater — a threshold oncologists treat as a meaningful treatment response. These are population-level aggregate figures. The MI-BET trial launched by GE HealthCare and Mayo Clinic is specifically designed to identify which patient characteristics predict individual response, since current practice cannot reliably separate likely responders from non-responders before treatment begins. Always discuss individual treatment decisions with a board-certified oncologist.
What are the side effects of PSMA radioligand therapy?
Side effects vary by patient and specific agent. Commonly reported effects include dry mouth (xerostomia), fatigue, nausea, and bone marrow suppression — effects associated with the radioactive component's off-target exposure. The therapy's targeted delivery mechanism is specifically designed to reduce radiation exposure to non-cancerous tissue compared to traditional radiation approaches, but it does not eliminate systemic exposure entirely. The MI-BET trial's outpatient monitoring pillar within GEMINI-RT is partly aimed at better characterizing and managing these effects using biomarker tracking. A treating oncologist is the right source for patient-specific side effect guidance.
The bottom line: When I look at the MI-BET trial's three-layer data architecture — imaging, biomarkers, and clinical outcomes feeding a unified predictive model — my read is that GE HealthCare and Mayo Clinic are building something more durable than a single research paper. They are laying the data infrastructure for the next generation of oncology AI tools. The theranostics market's projected climb from roughly $9.2 billion toward $31.5 billion by 2033 is the headline growth story, but the steeper upside emerges specifically if predictive biomarker tools can reduce the trial-and-error embedded in today's $40,000-per-cycle treatment decisions. That personalization layer is the real bet in this partnership — and it is one worth watching closely.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial, medical, or investment advice. The author is not a licensed financial advisor or qualified medical professional. Consult appropriate licensed professionals before making any financial or healthcare decisions. Research based on publicly available sources current as of July 10, 2026.